PHILADELPHIA (CBS) – New potential hope for millions of migraine sufferers. A new study says that a new class of migraine medications is promising.
The researchers say that treatment may be a better option for patients who are not helped by currently available medications.
Donna Esterine has been suffering from debilitating migraines for years.
"It's like acute pain in the forehead, eyes," said Esterine.
The 48-year-old mother of two says she missed family time and not working to try to cope.
"I would take a lot of sick days just because I could not take them, you know I should be at home and lie down," Esterine said.
Health experts sound the alarm about the dangers of plastic surgery after the deaths of three Americans in the Dominican Republic
She was taking classic anti-migraine medications called Triptans, but they made her nauseous. She then enrolled in a clinical trial to test a new drug called Rimegepant.
The drug belongs to a new generation of treatments that target a migraine molecule.
"There has been no new mechanism for the treatment of acute migraine on the market since the early 1990s," said Dr. Richard Lipton, of Einstein College of Medicine and Montefiore. .
A new study published in the New England Journal of Medicine reveals that Rimegepant effectively relieves pain and other symptoms, including nausea and sensitivity to light.
The research involved more than 1,000 men and women treating moderate to severe pain.
"People who have side effects to Triptans, people who do not respond to Triptans, people who have cardiovascular contraindications to the Triptans will be the ideal candidates for this drug," said Lipton.
A mysterious condition causing polio-like symptoms in children arrives early in Pennsylvania
The study also shows that the drug has very little side effects. Esterine says that she finally has relief from her migraines.
"She disappears so much faster that I feel good, I have no side effects," she said.
The company that makes the drug has sponsored the study and is applying to the Food and Drug Administration for approval and could get the green light in the next year.